tetano
Editor, Senior Moderator
Sci Rep
. 2025 Mar 23;15(1):10009.
doi: 10.1038/s41598-025-94801-9. A bioinformatics approach combined with experimental validation analyzes the efficacy of azithromycin in treating SARS-CoV-2 infection in patients with IPF and COPD These authors contributed equally: Yining Xie, Guangshu Chen, and Weiling Wu
Yining Xie[SUP] #[/SUP][SUP] 1 2 [/SUP], Guangshu Chen[SUP] #[/SUP][SUP] 1 [/SUP], Weiling Wu[SUP] #[/SUP][SUP] 1 [/SUP], Xueman Wen[SUP] 1 [/SUP], Meizheng Lai[SUP] 1 [/SUP], Li Che[SUP] 3 [/SUP], Jianmin Ran[SUP] 4 [/SUP]
Affiliations
The swift transmission rate and unfavorable prognosis associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have prompted the pursuit of more effective therapeutic interventions. Azithromycin (AZM) has garnered significant attention for its distinctive pharmacological mechanisms in the treatment of SARS-CoV-2. This study aims to elucidate the biological rationale for employing AZM in patients with chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) who are infected with SARS-CoV-2. Genetic data about COVID-19, COPD, and IPF were independently obtained from the GeneCards database. And 40 drug targets about AZM were retrieved from the STITCH database. The analysis revealed that 311 DEGs were common among COPD, IPF, and COVID-19, and we further found eight genes that interacted with AZM targets. We conducted an analysis of hub genes and their corresponding signaling pathways in these patient cohorts. Additionally, we explored the inhibitory effects of AZM on these hub genes. AZM demonstrated a significant inhibitory effect on eight key genes, except for AR and IL-17 A. These findings suggest that AZM may serve as a promising therapeutic agent for patients with COPD and IPF and SARS-CoV-2 infection.
Keywords: Azithromycin; Bioinformatics; COPD; IPF; SARS-Cov-2.
. 2025 Mar 23;15(1):10009.
doi: 10.1038/s41598-025-94801-9. A bioinformatics approach combined with experimental validation analyzes the efficacy of azithromycin in treating SARS-CoV-2 infection in patients with IPF and COPD These authors contributed equally: Yining Xie, Guangshu Chen, and Weiling Wu
Yining Xie[SUP] #[/SUP][SUP] 1 2 [/SUP], Guangshu Chen[SUP] #[/SUP][SUP] 1 [/SUP], Weiling Wu[SUP] #[/SUP][SUP] 1 [/SUP], Xueman Wen[SUP] 1 [/SUP], Meizheng Lai[SUP] 1 [/SUP], Li Che[SUP] 3 [/SUP], Jianmin Ran[SUP] 4 [/SUP]
Affiliations
- PMID: 40122903
- DOI: 10.1038/s41598-025-94801-9
The swift transmission rate and unfavorable prognosis associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have prompted the pursuit of more effective therapeutic interventions. Azithromycin (AZM) has garnered significant attention for its distinctive pharmacological mechanisms in the treatment of SARS-CoV-2. This study aims to elucidate the biological rationale for employing AZM in patients with chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) who are infected with SARS-CoV-2. Genetic data about COVID-19, COPD, and IPF were independently obtained from the GeneCards database. And 40 drug targets about AZM were retrieved from the STITCH database. The analysis revealed that 311 DEGs were common among COPD, IPF, and COVID-19, and we further found eight genes that interacted with AZM targets. We conducted an analysis of hub genes and their corresponding signaling pathways in these patient cohorts. Additionally, we explored the inhibitory effects of AZM on these hub genes. AZM demonstrated a significant inhibitory effect on eight key genes, except for AR and IL-17 A. These findings suggest that AZM may serve as a promising therapeutic agent for patients with COPD and IPF and SARS-CoV-2 infection.
Keywords: Azithromycin; Bioinformatics; COPD; IPF; SARS-Cov-2.